Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that omalizumab may induce alopecia, particularly in females aged 18-60, though establishing a direct cause-effect link remains challenging. Alopecia areata was noted as a possible uncommon, yet transient, hair loss type associated with omalizumab.

The document summarized various dermatology studies and case reports.

The congress showed that psychological therapy can help skin condition patients, social media affects acne stigma, education improves atopic dermatitis, and patient satisfaction in dermatology is high, especially with good doctor engagement.

This article discusses the role of hyperarousal and brain activity in insomnia and its potential link to sleep disturbances in depression, but it reports no new empirical findings.

Thyroid hormone may be useful for treating various skin conditions and needs more research.

Antiyeast treatments work better for seborrheic dermatitis than steroids, and other findings include increased skin bacteria under plastic wrap, a nasal cell defect in Staphylococcus aureus carriers, quick resolution of certain skin reactions, high rubber latex allergy in spina bifida patients, and glyceryl monopentadecanoate's effectiveness for male hair loss.

This report presents a rare case where a patient with chronic urticaria developed alopecia areata during azathioprine therapy, accompanied by bone marrow suppression; these effects resolved after stopping the medication, suggesting a possible link between azathioprine and autoimmune activation despite its intended immunosuppressive use.

This case report highlights an unusual instance of azathioprine potentially triggering rapid alopecia areata and bone marrow suppression in a patient with chronic spontaneous urticaria, with improvement seen after stopping the drug.

This case study from Dr. Batra’s discusses how individualized homeopathic management guided by miasmatic understanding may offer long-term relief for a young male patient with alopecia areata and recurrent urticaria, suggesting an alternative to conventional treatments that often result in relapses and side effects.

This article discusses common dermatologic side effects of psychopharmacologic agents such as eruptions, urticaria, and photosensitivity, but it reports no new research findings.

This study found that the most common skin disorders among perimenopausal Indian women were eczematous and urticaria, potentially linked to heightened sensitivity to environmental factors.

In this cross-sectional study of COVID-19 positive patients in Bangladesh, researchers found that maculo-papular eruptions were the most common dermatological manifestation, with other prevalent conditions including chilblain-like eruptions, urticarial lesions, and petechiae/purpura.

In this study, Covishield vaccination was associated with cutaneous adverse effects, notably telogen effluvium and urticaria, among recipients at a hospital in northern India.

This study observed a significant decrease in visits for acne, hair loss, and other non-severe skin conditions during COVID-19 lockdown, while conditions like urticaria and herpes zoster increased significantly.

This study reported common skin changes and symptoms associated with thyroid disorders, such as dry skin in hypothyroidism and warm, soft skin in hyperthyroidism, and noted urticaria as a frequent autoimmune association in hypothyroid patients.

This abstract provides no study findings; it outlines website features and permissions for accessing JAMA Network content.

Dermatologists should consider alpha-gal syndrome in patients with unexplained chronic skin issues.

This review discusses various skin manifestations associated with COVID-19, emphasizing their potential role in early diagnosis and management of the infection, but reports no new clinical findings.

This review focuses on the various skin symptoms associated with COVID-19 but reports no new clinical findings.

COVID-19 can cause various skin issues, including rashes and 'COVID toes', and may worsen autoimmune diseases or affect men with baldness more severely.

In this review, researchers highlighted that COVID-19 can cause various skin manifestations like maculopapular rashes and "COVID toes," which often precede or appear without respiratory symptoms, suggesting their potential for early detection and prognostic evaluation, especially in severe cases.

This review outlines the current state of stem cell therapy in dermatology, highlighting its potential for treating a variety of skin disorders and conditions, while emphasizing the need for further controlled studies to standardize treatment and fully understand its efficacy and limitations.

This case report describes a probable hypersensitivity reaction to a single intravenous dose of ondansetron, highlighting the need for cautious use, especially in outpatient settings.

This study reported that COVID-19 skin manifestations, such as exanthema and chilblains, varied in timing but resolved positively with proper treatment.

This review highlights recent literature on comorbidities in dermatologic diseases, emphasizing the need for further research into connections between atopic dermatitis and pancreatic cancer, and pemphigus diseases and COPD, but it reports no new clinical results.

This review discusses the various skin manifestations of COVID-19, aiming to improve early detection and treatment but reports no new clinical results.

This study reported that the increased dermatological emergency department visits during the pandemic, influenced by PPE usage and psychological stressors, highlight the need for more robust dermatology training and resources in emergency medicine to better prepare for future pandemics.

This review discusses the dermatologic side effects and potential therapeutic benefits of GLP-1 receptor agonists, such as facial fat loss and wound healing, emphasizing the need for further research.

Skin symptoms like rashes and hives can help identify COVID-19 early.

This study found that patients with vitiligo report the highest willingness-to-pay for disease control and cure compared to those with other chronic skin conditions, suggesting DLQI may not fully capture treatment priorities.